Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Mitomycin Generic Name & Formulations
Legal Class
Rx
General Description
Mitomycin 5mg/vial, 20mg/vial, 40mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.
Pharmacological Class
Cytotoxic antibiotic.
How Supplied
Contact supplier.
Manufacturer
Mitomycin Indications
Indications
Disseminated adenocarcinoma of the stomach.
Mitomycin Dosage and Administration
Adult
Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.
Children
Not recommended.
Mitomycin Contraindications
Contraindications
Thrombocytopenia. Coagulation disorders. Bleeding tendencies.
Mitomycin Boxed Warnings
Not Applicable
Mitomycin Warnings/Precautions
Warnings/Precautions
Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.
Mitomycin Pharmacokinetics
See Literature
Mitomycin Interactions
Interactions
Caution with vinca alkaloids, other chemotherapy.
Mitomycin Adverse Reactions
Adverse Reactions
Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.
Mitomycin Clinical Trials
See Literature
Mitomycin Note
Notes
Formerly known under the brand names Mitozytrex, Mutamycin.
Mitomycin Patient Counseling
See Literature
Mitomycin Generic Name & Formulations
Legal Class
Rx
General Description
Mitomycin 5mg/vial, 20mg/vial, 40mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.
Pharmacological Class
Cytotoxic antibiotic.
How Supplied
Contact supplier.
Manufacturer
Mitomycin Indications
Indications
Disseminated adenocarcinoma of the pancreas.
Mitomycin Dosage and Administration
Adult
Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.
Children
Not recommended.
Mitomycin Contraindications
Contraindications
Thrombocytopenia. Coagulation disorders. Bleeding tendencies.
Mitomycin Boxed Warnings
Not Applicable
Mitomycin Warnings/Precautions
Warnings/Precautions
Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.
Mitomycin Pharmacokinetics
See Literature
Mitomycin Interactions
Interactions
Caution with vinca alkaloids, other chemotherapy.
Mitomycin Adverse Reactions
Adverse Reactions
Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.
Mitomycin Clinical Trials
See Literature
Mitomycin Note
Notes
Formerly known under the brand names Mitozytrex, Mutamycin.
Mitomycin Patient Counseling
See Literature
